• Home
  • News
  • Calendar
  • About DF/HCC
  • Membership
  • Visitor Center

Ann Mullally, MD


  • De Vita S, Schneider RK, Garcia M, Wood J, Gavillet M, Ebert BL, Gerbaulet A, Roers A, Levine RL, Mullally A, Williams DA.Loss of function of TET2 cooperates with constitutively active KIT in murine and human models of mastocytosis.PLoS ONE. 2014;9(5):e96209.
  • Järås M, Miller PG, Chu LP, Puram RV, Fink EC, Schneider RK, Al-Shahrour F, Peña P, Breyfogle LJ, Hartwell KA, McConkey ME, Cowley GS, Root DE, Kharas MG, Mullally A, Ebert BL.Csnk1a1 inhibition has p53-dependent therapeutic efficacy in acute myeloid leukemia.J Exp Med. 2014 Apr 7;211(4):605-12.
  • Mullally A, Ebert BL.Sinister symbiosis: pathological hematopoietic-stromal interactions in CML.Cell Stem Cell. 2013 Sep 5;13(3):257-8.
  • Mullally A, Bruedigam C, Poveromo L, Heidel FH, Purdon A, Vu T, Austin R, Heckl D, Breyfogle LJ, Kuhn CP, Kalaitzidis D, Armstrong SA, Williams DA, Hill GR, Ebert BL, Lane SW.Depletion of Jak2V617F myeloproliferative neoplasm-propagating stem cells by interferon-α in a murine model of polycythemia vera.Blood. 2013 May 2;121(18):3692-702.
  • Mullally A, Ebert BL.Janus reveals another face: the biologic rationale for targeting janus kinase 2 in lymphoma.J Clin Oncol. 2012 Nov 20;30(33):4168-70.
  • Mullally A, Lane SW, Brumme K, Ebert BL.Myeloproliferative neoplasm animal models.Hematol Oncol Clin North Am. 2012 Oct;26(5):1065-81.
  • Koppikar P, Bhagwat N, Kilpivaara O, Manshouri T, Adli M, Hricik T, Liu F, Saunders LM, Mullally A, Abdel-Wahab O, Leung L, Weinstein A, Marubayashi S, Goel A, Gönen M, Estrov Z, Ebert BL, Chiosis G, Nimer SD, Bernstein BE, Verstovsek S, Levine RL.Heterodimeric JAK-STAT activation as a mechanism of persistence to JAK2 inhibitor therapy.Nature. 2012 Sep 6;489(7414):155-9.
  • Mullally A, Poveromo L, Schneider RK, Al-Shahrour F, Lane SW, Ebert BL.Distinct roles for long-term hematopoietic stem cells and erythroid precursor cells in a murine model of Jak2V617F-mediated polycythemia vera.Blood. 2012 Jul 5;120(1):166-72.
  • Mullally A, Ebert BL.STATistical power of clonal analysis: differential STAT1 pathway activation downstream of the JAK2V617F mutation.Cancer Cell. 2010 Nov 16;18(5):405-6.
  • Housman E, Chang P, Lane SW, Blinder R, Galinsky I, Kesari S, Ho VT, Stone RM, Mullally A.CNS relapse in acute promyeloctyic leukemia.J Clin Oncol. 2010 Aug 20;28(24):e409-11.
  • Mullally A, Ebert BL.NF1 inactivation revs up Ras in adult acute myelogenous leukemia.Clin Cancer Res. 2010 Aug 15;16(16):4074-6.
  • Mullally A, Lane SW, Ball B, Megerdichian C, Okabe R, Al-Shahrour F, Paktinat M, Haydu JE, Housman E, Lord AM, Wernig G, Kharas MG, Mercher T, Kutok JL, Gilliland DG, Ebert BL.Physiological Jak2V617F expression causes a lethal myeloproliferative neoplasm with differential effects on hematopoietic stem and progenitor cells.Cancer Cell. 2010 Jun 15;17(6):584-96.
  • Abdel-Wahab O,Mullally A,Hedvat C,Garcia-Manero G,Patel J,Wadleigh M,Malinge S,Yao J,Kilpivaara O,Bhat R,Huberman K,Thomas S,Dolgalev I,Heguy A,Paietta E,Le Beau MM,Beran M,Tallman MS,Ebert BL,Kantarjian HM,Stone RM,Gilliland DG,Crispino JD,Levine RL.Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies.Blood. 2009 Jul 2;114(1):144-7.
  • Kilpivaara O,Mukherjee S,Schram AM,Wadleigh M,Mullally A,Ebert BL,Bass A,Marubayashi S,Heguy A,Garcia-Manero G,Kantarjian H,Offit K,Stone RM,Gilliland DG,Klein RJ,Levine RL.A germline JAK2 SNP is associated with predisposition to the development of JAK2(V617F)-positive myeloproliferative neoplasms.Nat Genet. 2009 Apr;41(4):455-9.
  • Mullally A, Ritz J.Beyond HLA: the significance of genomic variation for allogeneic hematopoietic stem cell transplantation.Blood. 2007 Feb 15;109(4):1355-62. Review.
  • Mullally AM, Vogelsang GB, Moliterno AR.Wasted sheep and premature infants: the role of trace metals in hematopoiesis.Blood Rev. 2004 Dec;18(4):227-34. Review.